Human PD-L1 inhibitor V

• CAT Number: I044286
• CAS Number: 2815311-61-4
• Molecular Formula: C65H104N20O18S
• Molecular Weight: 1485.71
• Purity: ≥95%
• IUPAC Name: (2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylpentanoyl]amino]-3-carboxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylbutanoyl]amino]-4-oxobutanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-4-methylsulfanylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-5-oxopentanoic acid
• InChI: InChI=1S/C65H104N20O18S/c1-33(2)28-39(67)53(92)81-48(32-51(90)91)60(99)83-46(30-36-15-19-38(87)20-16-36)61(100)85-52(34(3)4)62(101)84-47(31-50(69)89)59(98)78-42(12-9-26-75-65(72)73)56(95)77-41(11-8-25-74-64(70)71)55(94)76-40(10-6-7-24-66)54(93)79-43(23-27-104-5)57(96)82-45(29-35-13-17-37(86)18-14-35)58(97)80-44(63(102)103)21-22-49(68)88/h13-20,33-34,39-48,52,86-87H,6-12,21-32,66-67H2,1-5H3,(H2,68,88)(H2,69,89)(H,76,94)(H,77,95)(H,78,98)(H,79,93)(H,80,97)(H,81,92)(H,82,96)(H,83,99)(H,84,101)(H,85,100)(H,90,91)(H,102,103)(H4,70,71,74)(H4,72,73,75)/t39-,40-,41-,42-,43-,44-,45-,46-,47-,48-,52-/m0/s1
• InChIKey: TWQFYTLFODMZIW-WIRYOQIKSA-N
• SMILES: CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N

Human PD-L1 Inhibitor V（Cat No.:I044286）is a synthetic peptide designed to block the interaction between Programmed Death-Ligand 1 (PD-L1) and its receptor PD-1, a pathway that tumors exploit to evade immune surveillance. By inhibiting this binding, the peptide restores T-cell activation and enhances immune responses against cancer cells. PD-L1 Inhibitor V is used in immuno-oncology research to explore checkpoint blockade mechanisms and evaluate novel therapeutic strategies. It offers a valuable alternative to antibody-based inhibitors, with potential advantages in tissue penetration, manufacturing, and reduced immunogenicity for cancer immunotherapy development.